Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia 2014
Our presence worldwide
Today, our company has 40 employees with 13 nationalities. Its operations are done throughout several countries thanks to 3 offices: Moleac Singapore (headquarters), Moleac Europe and Poland and through exclusive partnerships
Moleac’s Multi-Modal Approach to Treatment for Brain Injuries
Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.
The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials. Moleac takes on a multi-model strategy in its approach to drug development.
What is Stroke?
Stroke is a devastating disease affecting 17 million victims worldwide. It is a leading cause of adult acquired disability in many countries. Stroke is a medical emergency. Do not wait! The longer a patient waits, the more damage happens to the brain. After a stroke, an estimated 2 million brain cells, called neurons, die every minute without treatment.
Moleac has brought to market the first drug that helps patients recover faster and better from their stroke disabilities.
NeuroAiD™ (MLC 601, MLC 901) addresses these gaps in pharmacological modalities which combined to a rehabilitation program offers new hopes to patients who had no other choice than to cope with their disabilities.